Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $16.3 million.

  • Tarsus Pharmaceuticals' Free Cash Flow rose 28297.52% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.5 million, marking a year-over-year increase of 4341.19%. This contributed to the annual value of -$84.6 million for FY2024, which is 2890.96% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Free Cash Flow is $16.3 million, which was up 28297.52% from -$30.4 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Free Cash Flow ranged from a high of $20.5 million in Q2 2021 and a low of -$39.3 million during Q4 2023
  • For the 5-year period, Tarsus Pharmaceuticals' Free Cash Flow averaged around -$15.0 million, with its median value being -$15.4 million (2022).
  • Within the past 5 years, the most significant YoY rise in Tarsus Pharmaceuticals' Free Cash Flow was 81006.22% (2021), while the steepest drop was 48902.56% (2021).
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Free Cash Flow stood at -$12.4 million in 2021, then increased by 11.25% to -$11.0 million in 2022, then tumbled by 257.56% to -$39.3 million in 2023, then soared by 43.42% to -$22.3 million in 2024, then soared by 173.46% to $16.3 million in 2025.
  • Its Free Cash Flow stands at $16.3 million for Q3 2025, versus -$30.4 million for Q2 2025 and -$21.2 million for Q1 2025.